Arrow™ EZ-IO™
Intraosseous Vascular Access System
Intraosseous Vascular Access System
In patients with DVA, central venous catheter (CVC) access and peripheral IV (PIV) access can take longer and are less likely to be successful when compared with IO.5,6
The Arrow™ EZ-IO™ System delivers the performance you need when there’s no time to lose. Backed by more than 15 years of clinical research and proven success7, the EZ-IO™ System is a fast8 and effective9 solution for patients with difficult vascular access (DVA) that delivers the speed you need, success you depend on and safety profile you trust.
Sepsis Kills a Patient in the U.S. Every 2.3 Minutes11
Overall, it kills more than AIDS and breast, colon, pancreatic, and prostate cancer combined12,1 3
As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment14
IV fluid resuscitation initiation administered within 30 minutes may decrease sepsis mortality rates and hospital length of stay15
Early antibiotics—ideally within the first hour—make a difference16
A study has shown that mortality increases 7.6% for every hour of delay in IV antibiotics14
Get in touch with our experts and learn how this device can elevate your services.
Arrow® EZ-IO® System
Arrow® EZ-IO® System
Rx Only.
The Arrow™ EZ-IO™ Needle Set is Sterile, Single Use: Do not reuse, reprocess or re-sterilize. Reuse of device creates a potential risk of serious injury and/or infection which may lead to death. Refer to Instructions for Use for complete warnings, indications, contraindications, precautions, and potential complications.
Not all products shown on the website may be approved in all regulatory jurisdictions. Consult with your local Teleflex representative for details.
References
1. Donnino MW, et al. BMJ. 2014; 2. Gayet-Ageron A, et al. 2018; 3. Ferrer R, et al. Crit Care Med. 2014; 4. Fonarow GC, et al. Circulation. 2011; 5. Lee PJ, et al. Crit Care Med. 2015; 6. Ross EM, et al. Am J Disaster Med. 2016; 7. Dolister M, et al. J Vasc Access. 2013. Research sponsored by Teleflex Incorporated; 8. Davidoff J, et al. JEMS. 2005. Research sponsored by Teleflex Incorporated; 9. Montez DF, et al. Ann Emerg Med. 2015. Research sponsored by Teleflex Incorporated; 10. Leidel BA, et al. Resuscitation. 2012; 11. Marik PE. Ann Intensive Care. 2011; 12. HIV in the United States: at a glance. Centers for Disease Control and Prevention Website. http://www.cdc.gov/hiv/statistics/basics/ataglance.html. Updated September 9, 2019. Accessed 23 Aug, 2023; 13. American Cancer Society Website. Cancer Facts & Figures 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. Accessed 23 Aug, 2023; 14. Kumar et al. Crit Care Med. 2006; 15. Leisman D, et al. Annals of Emergency Medicine. 2016; 16. Dellinger, R. 2014; 17. Mozaffarian D, et al: Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015; 18. Clemency B, et al. Am J Emerg Med. 2016. 19. Bramlett E, et al. Ann Emerg Med. 2016; 20. Based on Adult Proximal Humerus EZ-IO™ insertion data; 21. Compared to single lumen CVCs; 22. Hoskins SL, et al. Circulation 2007. Research sponsored by Teleflex Incorporated. (preclinical study); 23. Hoskins SL, et al. Resuscitation. 2011. Research sponsored by Teleflex Incorporated. (preclinical study); 24. Philbeck TE, et al. JEMS. 2010. Research sponsored by Teleflex Incorporated; 25. Cooper BR, et al. J R Army Med Corps. 2007; 26. Teleflex Internal Data on File 2018; 27. Puga T, et al. Crit Care Med 2016. Research sponsored by Teleflex Incorporated. Based on healthy volunteer study; 28. Truemper EJ, et al. Ann Emerg. Med 2012. Research sponsored by Teleflex Incorporated.
*Epinephrine administered in hospital cardiac arrest.
**The Arrow™ EZ-IO™ System is indicated for intraosseous access anytime in which vascular access is difficult to obtain in emergent, urgent or medically necessary cases for up to 24 hours. For patients ≥ 12 years old, the device may be extended for up to 48 hours when alternate intravenous access is not available or reliably established.
***Time to access is measured as insertion of the needle set through the bone cortex and into the intraosseous space.
****Based on adult proximal humerus study conducted in healthy individual.
† Analysis limited to administration of tranexamic acid.Data captured until 3 hours had elapsed.
‡Door-to-needle time for tPA.
#Time measured is patient arrival to the first dose of epinephrine.
Teleflex, Teleflex logo, AC3 Optimus, Arrow, Arrowg+ard, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, and EZ-IO are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. All other trademarks or registered trademarks appearing on the web site are the property of their respective owners.
.png){kind=small}
